The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Plexxikon
Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Agenus; Castle Biosciences; Daiichi Sankyo; Deciphera; Imaging Endpoints; Neon Therapeutics; RedHill Biopharma; Salarius Pharmaceuticals; TRACON Pharma
Research Funding - AADi (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Agenus (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Beigene (Inst); BeiGene (Inst); BiolineRx (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); CanBas (Inst); cantex (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); FibroGen (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genocea Biosciences (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Helix BioPharma (Inst); Hengrui Therapeutics (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Inhibrx (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Revolution Medicines (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Syndax (Inst); SynDevRx (Inst); Syros Pharmaceuticals (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); TTC Oncology (Inst); Verastem (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Richard D. Carvajal
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Genzyme; Genzyme; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Gritstone Bio; incyte; Jazz Pharmaceuticals; Merck (Inst); Mirati Therapeutics; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Takeda (Inst); Trovagene (Inst)
 
Marilyn Huang
Consulting or Advisory Role - Aptitude Health; Seagen; Tesaro
 
Paul Watkins
Employment - Plexxikon
 
Ben Powell
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
Patents, Royalties, Other Intellectual Property - Plexxikon
 
Kerry Inokuchi
No Relationships to Disclose
 
Michael Sterba
Employment - Plexxikon
Stock and Other Ownership Interests - Rigel
 
Bernice Matusow
Employment - Plexxikon
Stock and Other Ownership Interests - Daiichi Sankyo
 
Chelsea Hope
Employment - Plexxikon
Patents, Royalties, Other Intellectual Property - University of Wisconsin, Madison
 
Jason Halladay
Employment - Plexxikon
 
Chao Zhang
Employment - Plexxikon
Leadership - Plexxikon
Research Funding - Plexxikon
 
Jacqueline M. Walling
Leadership - Arch Oncology; Nurix; Plexxikon
Consulting or Advisory Role - Aduro Biotech; Amgen; Aminex; Arch Oncology; Crown Bioscience; CytomX Therapeutics; Flag Therapeutics; Grace Science; Harpoon Therapeutics; ImmuNext; January Therapeutics; Leap Therapeutics; Myovant Sciences; Nurix; Pharm Olam; Plexxikon; Prothena; Puma Biotechnology; QUE Oncology; Que Oncology; Rhizen Pharmaceuticals; Sesen Bio; Shanghai Pharma; ShapeTx; Stealth Biotherapeutics; TRex Bio; Upsher-Smith
Expert Testimony - Puma Biotechnology
 
Athanasios C. Tsiatis
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
Patents, Royalties, Other Intellectual Property - Genomic Health-Proprietary (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Plexxikon
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Ionova (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Sanofi (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)